GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Yunkang Group Ltd (HKSE:02325) » Definitions » ROE %

Yunkang Group (HKSE:02325) ROE % : -13.76% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Yunkang Group ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Yunkang Group's annualized net income for the quarter that ended in Dec. 2023 was HK$-330.3 Mil. Yunkang Group's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was HK$2,399.7 Mil. Therefore, Yunkang Group's annualized ROE % for the quarter that ended in Dec. 2023 was -13.76%.

The historical rank and industry rank for Yunkang Group's ROE % or its related term are showing as below:

HKSE:02325' s ROE % Range Over the Past 10 Years
Min: -6.2   Med: 7.2   Max: 30.89
Current: -4.4

During the past 6 years, Yunkang Group's highest ROE % was 30.89%. The lowest was -6.20%. And the median was 7.20%.

HKSE:02325's ROE % is ranked better than
51.9% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.965 vs HKSE:02325: -4.40

Yunkang Group ROE % Historical Data

The historical data trend for Yunkang Group's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yunkang Group ROE % Chart

Yunkang Group Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -3.90 28.75 30.89 18.30 -4.35

Yunkang Group Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only 30.95 23.60 11.19 4.01 -13.76

Competitive Comparison of Yunkang Group's ROE %

For the Diagnostics & Research subindustry, Yunkang Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yunkang Group's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Yunkang Group's ROE % distribution charts can be found below:

* The bar in red indicates where Yunkang Group's ROE % falls into.



Yunkang Group ROE % Calculation

Yunkang Group's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-111.849/( (2827.815+2310.227)/ 2 )
=-111.849/2569.021
=-4.35 %

Yunkang Group's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-330.264/( (2489.133+2310.227)/ 2 )
=-330.264/2399.68
=-13.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Yunkang Group  (HKSE:02325) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-330.264/2399.68
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-330.264 / 907.038)*(907.038 / 4982.313)*(4982.313 / 2399.68)
=Net Margin %*Asset Turnover*Equity Multiplier
=-36.41 %*0.1821*2.0762
=ROA %*Equity Multiplier
=-6.63 %*2.0762
=-13.76 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-330.264/2399.68
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-330.264 / -301.052) * (-301.052 / -61.052) * (-61.052 / 907.038) * (907.038 / 4982.313) * (4982.313 / 2399.68)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.097 * 4.9311 * -6.73 % * 0.1821 * 2.0762
=-13.76 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Yunkang Group ROE % Related Terms

Thank you for viewing the detailed overview of Yunkang Group's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yunkang Group (HKSE:02325) Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Lizhishan Road, Science City, Huangpu District, Guangzhou, CHN
Yunkang Group Ltd is a medical operation service provider in China. The company has three major business lines namely covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and non-medical institutions.
Executives
Huizekx Limited 2201 Interest of corporation controlled by you
Yk Development Limited 2101 Beneficial owner
Zhang Yong 2201 Interest of corporation controlled by you
Shanghai Pudong Development Bank Co., Ltd 2201 Interest of corporation controlled by you
Zhou Xinyu
Guang Zhou Da An Ji Yin Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Da An Guo Ji Ji Tuan You Xian Gong Si 2101 Beneficial owner
Guang Zhou Shi Da An Ji Yin Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Jin Jun Ying Limited 2201 Interest of corporation controlled by you
Mouduans Limited 2201 Interest of corporation controlled by you
Source Capital Rw Limited 2201 Interest of corporation controlled by you
Tongfuzc Limited 2201 Interest of corporation controlled by you
Wjjr Investment Limited 2201 Interest of corporation controlled by you

Yunkang Group (HKSE:02325) Headlines

No Headlines